FigureĀ 1.
Engraftment. (A-B) Cumulative incidences of neutrophil (A) and platelet (B) engraftment of the UM171 CB cohort (UM171) and the CIBMTR CB controls (UCB). Neutrophil and platelet engraftment are improved in the UM171 CB cohort by Gray test. (C-D) Cumulative incidences of neutrophil (A) and platelet (B) engraftment of the UM171 CB cohort and the CIBMTR MUD PBSC controls (PBSC). Platelet engraftment is delayed for UM171 CB compared with MUD PBSC by Gray test.

Engraftment. (A-B) Cumulative incidences of neutrophil (A) and platelet (B) engraftment of the UM171 CB cohort (UM171) and the CIBMTR CB controls (UCB). Neutrophil and platelet engraftment are improved in the UM171 CB cohort by Gray test. (C-D) Cumulative incidences of neutrophil (A) and platelet (B) engraftment of the UM171 CB cohort and the CIBMTR MUD PBSC controls (PBSC). Platelet engraftment is delayed for UM171 CB compared with MUD PBSC by Gray test.

Close Modal

or Create an Account

Close Modal
Close Modal